Harmony Biosciences Holdings (HRMY) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn | -28.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.69% |
| Dec 31, 2025 | -52.98% |
| Sep 30, 2025 | 10.35% |
| Jun 30, 2025 | 243.16% |
| Mar 31, 2025 | 18.85% |
| Dec 31, 2024 | 196.69% |
| Sep 30, 2024 | 19.84% |
| Jun 30, 2024 | -66.21% |
| Mar 31, 2024 | 30.01% |
| Dec 31, 2023 | 171.08% |
| Sep 30, 2023 | -56.27% |
| Jun 30, 2023 | 45.77% |
| Mar 31, 2023 | 37.24% |
| Dec 31, 2022 | -264.81% |
| Sep 30, 2022 | 1,014.17% |
| Jun 30, 2022 | 66.69% |
| Mar 31, 2022 | 190.89% |
| Dec 31, 2021 | 11,020.19% |
| Sep 30, 2021 | -134.41% |
| Jun 30, 2021 | 234.79% |
| Mar 31, 2021 | 115.05% |
| Dec 31, 2020 | 99.55% |
| Sep 30, 2020 | 89.97% |